FibroBiologics, Inc.
FBLG
$0.26
-$0.02-5.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 0.09% | 14.21% | 22.30% | 31.44% | 41.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.19% | 42.10% | 43.54% | 47.09% | 54.53% |
| Operating Income | -21.19% | -42.10% | -43.54% | -47.09% | -54.53% |
| Income Before Tax | -67.06% | -4.06% | 32.09% | 65.97% | 32.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -67.06% | -4.06% | 32.09% | 65.97% | 32.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -67.06% | -4.06% | 32.09% | 65.97% | 32.30% |
| EBIT | -21.19% | -42.10% | -43.54% | -47.09% | -54.53% |
| EBITDA | -20.79% | -41.90% | -43.26% | -46.53% | -53.58% |
| EPS Basic | -26.86% | 20.30% | 45.71% | 72.25% | 48.16% |
| Normalized Basic EPS | -26.89% | 20.27% | 45.69% | 72.26% | 40.08% |
| EPS Diluted | -26.86% | 20.30% | 45.71% | 72.25% | 48.16% |
| Normalized Diluted EPS | -26.89% | 20.27% | 45.69% | 72.26% | 40.08% |
| Average Basic Shares Outstanding | 35.79% | 21.42% | 18.82% | 18.31% | 16.45% |
| Average Diluted Shares Outstanding | 35.79% | 21.42% | 18.82% | 18.31% | 16.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |